Five pictures to understand EGFR Exon20 inhibitor

1

EGFR exon 20 insertion mutation accounts for about 10% of all cancer EGFR mutations, and is the third most common mutation after EGFR exon 19 deletion (19Del) and exon 21 mutation (L858R)

2

EGFR INS20 mutations are distributed in the C-helical domain of exon 20 and its terminal loop region

3

In the past 3 years, more than 5 new drugs targeting EGFR INS20 mutations have entered clinical research and development and have shown potential therapeutic effects

4

As of February 12, 2021, the research data and ongoing clinical trials of EGFR INS20 targeted therapy for the NSCLC population are summarized as shown in the table below

5

In the fifth edition of the NCCN NSCLC guidelines in 2021, the treatment process for patients with EGFR exon 20 insertion mutations has been added, including: amivantamab as a platinum-based chemotherapy ± follow-up treatment for patients with progress in immunotherapy, the level of evidence is 2A recommendation

The NCCN guidelines expert group's recommendation for amivantamab (EGFR/MET bispecific antibody) is based on the results of the phase I CHRYSALIS trial

The results of the study showed that after 9.

Source: NextMed database

References: Meador CB, Sequist LV, Piotrowska Z.